Cost-effectiveness of Initiating an Insulin Pump in T1D Adults Using Continuous Glucose Monitoring Compared with Multiple Daily Insulin Injections: The DIAMOND Randomized Trial

被引:13
作者
Wan, Wen [1 ]
Skandari, M. Reza [1 ]
Minc, Alexa [1 ]
Nathan, Aviva G. [1 ]
Zarei, Parmida [1 ]
Winn, Aaron N. [2 ]
O'Grady, Michael [3 ]
Huang, Elbert S. [1 ]
机构
[1] Univ Chicago, Sect Gen Internal Med, 5841 S Maryland Ave,MC 2007, Chicago, IL 60637 USA
[2] Med Coll Wisconsin, Sch Pharm, Milwaukee, WI 53226 USA
[3] Univ Chicago, Natl Opin Res Ctr, Chicago, IL 60637 USA
关键词
continuous glucose monitoring; cost-effectiveness; insulin pump; randomized clinical trial; type; 1; diabetes; GLYCEMIC CONTROL; DIABETES INTERVENTIONS; TYPE-1; HEALTH; HYPOGLYCEMIA; THERAPY; PEOPLE; INFUSION; OUTCOMES; MODEL;
D O I
10.1177/0272989X18803109
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background. The economic impact of both continuous glucose monitoring (CGM) and insulin pumps (continuous subcutaneous insulin infusion [CSII]) in type 1 diabetes (T1D) have been evaluated separately. However, the cost-effectiveness of adding CSII to existing CGM users has not yet been assessed. Objective. The aim of this study was to evaluate the societal cost-effectiveness of CSII versus continuing multiple daily injections (MDI) in adults with T1D already using CGM. Methods. In the second phase of the DIAMOND trial, 75 adults using CGM were randomized to either CGM+CSII or CGM+MDI (control) and surveyed at baseline and 28 weeks. We performed within-trial and lifetime cost-effectiveness analyses (CEAs) and estimated lifetime costs and quality-adjusted life-years (QALYs) via a modified Sheffield T1D model. Results. Within the trial, the CGM+CSII group had a significant reduction in quality of life from baseline (-0.02 +/- 0.05 difference in difference [DiD]) compared with controls. Total per-person 28-week costs were $8,272 (CGM+CSII) versus $5,623 (CGM+MDI); the difference in costs was primarily attributable to pump use ($2,644). Pump users reduced insulin intake (-12.8 units DiD) but increased the use of daily number of test strips (+1.2 DiD). Pump users also increased time with glucose in range of 70 to 180 mg/dL but had a higher HbA1c (+0.13 DiD) and more nonsevere hypoglycemic events. In the lifetime CEA, CGM+CSII would increase total costs by $112,045 DiD, decrease QALYs by 0.71, and decrease life expectancy by 0.48 years. Conclusions. Based on this single trial, initiating an insulin pump in adults with T1D already using CGM was associated with higher costs and reduced quality of life. Additional evidence regarding the clinical effects of adopting combinations of new technologies from trials and real-world populations is needed to confirm these findings.
引用
收藏
页码:942 / 953
页数:12
相关论文
共 50 条
  • [21] Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections A Randomized Trial
    Beck, Roy W.
    Riddlesworth, Tonya D.
    Ruedy, Katrina
    Ahmann, Andrew
    Haller, Stacie
    Kruger, Davida
    McGill, Janet B.
    Polonsky, William
    Price, David
    Aronoff, Stephen
    Aronson, Ronnie
    Toschi, Elena
    Kollman, Craig
    Bergenstal, Richard
    [J]. ANNALS OF INTERNAL MEDICINE, 2017, 167 (06) : 365 - +
  • [22] A Cost-Effectiveness Analysis of Continuous Subcutaneous Insulin Injection versus Multiple Daily Injections in Type 1 Diabetes Patients: A Third-Party US Payer Perspective
    St Charles, Meaghan
    Lynch, Peter
    Graham, Claudia
    Minshall, Michael E.
    [J]. VALUE IN HEALTH, 2009, 12 (05) : 674 - 686
  • [23] Prediction of Nocturnal Hypoglycemia in Adults with Type 1 Diabetes under Multiple Daily Injections Using Continuous Glucose Monitoring and Physical Activity Monitor
    Bertachi, Arthur
    Vinals, Clara
    Biagi, Lyvia
    Contreras, Ivan
    Vehi, Josep
    Conget, Ignacio
    Gimenez, Marga
    [J]. SENSORS, 2020, 20 (06)
  • [24] Flash glucose monitoring and automated bolus calculation in type 1 diabetes treated with multiple daily insulin injections: a 26 week randomised, controlled, multicentre trial
    Secher, Anna Lilja
    Pedersen-Bjergaard, Ulrik
    Svendsen, Ole L.
    Gade-Rasmussen, Birthe
    Almdal, Thomas
    Raimond, Linda
    Vistisen, Dorte
    Norgaard, Kirsten
    [J]. DIABETOLOGIA, 2021, 64 (12) : 2713 - 2724
  • [25] A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial
    Heller, Simon
    White, David
    Lee, Ellen
    Lawton, Julia
    Pollard, Daniel
    Waugh, Norman
    Amiel, Stephanie
    Barnard, Katharine
    Beckwith, Anita
    Brennan, Alan
    Campbell, Michael
    Cooper, Cindy
    Dimairo, Munyaradzi
    Dixon, Simon
    Elliott, Jackie
    Evans, Mark
    Green, Fiona
    Hackney, Gemma
    Hammond, Peter
    Hallowell, Nina
    Jaap, Alan
    Kennon, Brian
    Kirkham, Jackie
    Lindsay, Robert
    Mansell, Peter
    Papaioannou, Diana
    Rankin, David
    Royle, Pamela
    Smithson, W. Henry
    Taylor, Carolin
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2017, 21 (20) : 1 - +
  • [26] Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial
    Aronson, R.
    Reznik, Y.
    Conget, I.
    Castaneda, J. A.
    Runzis, S.
    Lee, S. W.
    Cohen, O.
    [J]. DIABETES OBESITY & METABOLISM, 2016, 18 (05) : 500 - 507
  • [27] Cost-effectiveness of insulin pumps compared with multiple daily injections both provided with structured education for adults with type 1 diabetes: a health economic analysis of the Relative Effectiveness of Pumps over Structured Education (REPOSE) randomised controlled trial
    Pollard, Daniel John
    Brennan, Alan
    Dixon, Simon
    Waugh, Norman
    Elliott, Jackie
    Heller, Simon
    Lee, Ellen
    Campbell, Michael
    Basarir, Hasan
    White, David
    [J]. BMJ OPEN, 2018, 8 (04):
  • [28] Cost-Effectiveness Analysis of a Hybrid Closed-Loop System Versus Multiple Daily Injections and Capillary Glucose Testing for Adults with Type 1 Diabetes
    Pease, Anthony
    Zomer, Ella
    Liew, Danny
    Earnest, Arul
    Soldatos, Georgia
    Ademi, Zanfina
    Zoungas, Sophia
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 (11) : 812 - 821
  • [29] Optimization of Insulin Regimen and Glucose Outcomes with Short-Term Real-Time Continuous Glucose Monitoring in Adult Type 1 Diabetic Patients with Suboptimal Control on Multiple Daily Injections: The Adult DIACCOR Study
    Picard, Sylvie
    Hanaire, Helene
    Reznik, Yves
    Benhamou, Pierre-Yves
    Fendri, Salha
    Dufaitre, Lise
    Leutenegger, Eric
    Guerci, Bruno
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 (06) : 403 - 412
  • [30] The effects of three months long continuous glucose monitoring in children with type 1 diabetes on multiple daily insulin injections
    Bukara-Radujkovic, Gordana
    Miljkovic, Vesna
    Lakic, Sinisa
    [J]. VOJNOSANITETSKI PREGLED, 2018, 75 (12) : 1209 - 1215